President, Chief Executive Officer and Director · Lyell Immunopharma, Inc. (LYEL)

Lynn Seely

A named executive officer of Lyell Immunopharma in every fiscal year CompBrief holds from FY2022 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$4,222,265

FY2024: $1,495,376

1st of 3 named executive officers at Lyell Immunopharma by FY2025 total.

3 named officers on file for Lyell Immunopharma, FY2025

See an example →

What this number hides

The filing gives the total. Lyell Immunopharma’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed April 24, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-06.

Free

Get Lynn Seely’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Lynn Seely and every company like it: Velarion Intel, free for 3 days, no card →

Lynn Seely compensation by year

Lyell Immunopharma Summary Compensation Table · all 4 fiscal years held
In US dollars, as Lyell Immunopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024FY2025
Salary$30,000$650,000$675,962$690,173
Bonus$0$0$0$0
Stock awards$0$0$474,000$186,806
Option awards$18,640,500$1,685,250$0$2,907,551
Non-equity incentive$0$292,500$324,000$414,000
Pension and deferred compensation$0$0$0$0
All other$15,689$19,726$21,414$23,735
Total$18,686,189$2,647,476$1,495,376$4,222,265

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Lyell Immunopharma, Inc. DEF 14A filed April 24, 2026, accession 0001140361-26-016686, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Lyell Immunopharma, Inc. filed document, accession 0001140361-26-016686. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.

$18.7M
$2.6M
$1.5M
$4.2M
FY22
FY23
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
PSU25,000$769,500—
RSU20,000$615,600—
RSU13,710$421,994—
Option53,432—$11.07
Option175,000—$17.23

Per the Outstanding Equity Awards at Fiscal Year-End table in Lyell Immunopharma, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

3 Form 4 lines since the FY2025 proxy (filed April 24, 2026)
current to 2026-11-06 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-08-21Sale—9,589$15.5463,899
2026-08-10Sale—390$14.3473,488
2026-05-11Sale—388$18.9173,878

The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Lyell Immunopharma’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Lynn Seely · this pagePresident, Chief Executive Officer and Director$4,222,265
Stephen HillChief Operating Officer$2,076,439
Gary LeeChief Scientific Officer$1,942,621

Board service

Lyell Immunopharma board · FY2021–FY2025
Director compensation in US dollars, as Lyell Immunopharma reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$0$0$0$0—
FY2024—————
FY2023—————
FY2022$55,000—$249,223—$304,223
FY2021$32,675$0$4,572,827—$4,605,502

Each year as the company reported it in Lyell Immunopharma's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Lyell Immunopharma pays directors a $50,000 cash retainer and $300,000 in Options. As stated in Lyell Immunopharma's FY2025 proxy.

The full Lyell Immunopharma compensation record

free company brief

This page is one person within Lyell Immunopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Lyell Immunopharma's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Lyell Immunopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order LYEL

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Lynn Seely's compensation dossier